Antibiotic prophylaxis and its appropriate timing for urological surgical procedures in patients with asymptomatic bacteriuria: a systematic review by Ramos, Jorge et al.
Arab Journal of Urology (2016) 14, 234–239Arab Journal of Urology
(Official Journal of the Arab Association of Urology)
www.sciencedirect.comGENERAL UROLOGY
REVIEWAntibiotic prophylaxis and its appropriate timing
for urological surgical procedures in patients with
asymptomatic bacteriuria: A systematic review* Corresponding author. Tel.: +57 301 6701077.
E-mail address: jormos2806@gmail.com (J.A. Ramos).
Peer review under responsibility of Arab Association of Urology.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.aju.2016.05.002
2090-598X  2016 Arab Association of Urology. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Jorge A. Ramos





d,eaUniversidad CES, Medellı́n, Colombia
bService of Infectious Diseases, Hospital Universitario de Neiva, Colombia
cSchool of Health Sciences, Fundación Universitaria Navarra, Colombia
dDepartment of Preventive Medicine and Public Health, Universidad de Santiago de Compostela, Spain
eCIBER of Epidemiology and Public Health, CIBERESP, Madrid, SpainReceived 20 March 2016, Received in revised form 10 April 2016, Accepted 9 May 2016










bacteriuriaAbstract Objective: To review the existing literature on when and how to treat
patients with asymptomatic bacteriuria (AB) who undergo urological surgery, as
uncertainty about this issue persists.
Methods: A systematic review was conducted to compare the different timing of
administration of antibiotic prophylaxis in patients with AB undergoing urological
surgery. We used predefined inclusion and exclusion criteria, and we also developed
a specific quality scale to assess the quality of the papers included.
Results: Nine studies met the inclusion criteria. Of the nine studies included, eight
evaluated antibiotic prophylaxis regardless of the presence of AB, as their purpose
was to evaluate the effectiveness of antibiotic prophylaxis for urological procedures.
Of these, four studies showed a significant reduction in the rate of infections in the
intervention group compared with placebo, or with the same antibiotic therapy but
using different durations of therapy. Four studies found no significant differences in
infectious complications between the intervention and comparison arms. Only one
study assessed the duration of antibiotic prophylaxis in patients with AB.
Antibiotic prophylaxis in patients with asymptomatic bacteriuria 235Conclusions: With the available evidence, antibiotic therapy should be considered
only for procedures in which studies have shown a clinical benefit in the prevention
of infection. It is important to establish the duration and type of treatment for
antimicrobial therapy for surgical prophylaxis in patients with AB who are going
to receive urological invasive procedures.
 2016 Arab Association of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
Asymptomatic bacteriuria (AB) or urinary tract coloni-
sation is defined as the isolation of bacteria in a urine
sample collected properly from a person who has no
signs or symptoms of a UTI [1]. This colonisation of
the urinary tract is common in diabetic women, with a
prevalence of 8–14% [2], in pregnant women (2–7%)
[3], in men aged >60 years (6–15%) [4], and in patients
with spinal cord injury, with a prevalence rate of >50%
[5].
There is clinical evidence that AB should be treated in
pregnant women because it decreases the risk of
pyelonephritis by between 4% and 20% [6], and reduces
the risk of premature birth [7]. Antibiotic therapy should
be used for patients with AB who are going to undergo
urological surgery due to a 60% risk of presenting with
infectious complications such as bacteraemia and a 10%
risk of sepsis [1].
For this condition, some clinical trials have shown
that antibiotic prophylaxis in patients with AB decreases
the risk of bacteraemia and sepsis in the postoperative
period [1]; but there is no consensus on the treatment
type or when to start antibiotic therapy. Studies have
started prophylaxis from 1 to 7 days before the proce-
dure [8], without determining the differences in the
results for each intervention.
For this reason it is important establish the appropri-
ate therapy and the ideal starting time of antibiotic pro-
phylaxis to prevent surgical infections in urological
procedures in patients with AB, with the aim of reducing
the potential morbidity for these patients and also to
reduce costs. To answer this question we performed a
systematic review of the scientific literature.Methods
Study design
We systematically reviewed the scientific literature fol-
lowing the Patient, Intervention, Comparison, and Out-
come (PICO) scheme. The patients were individuals with
AB with urological surgery scheduled. The intervention
was antibiotic prophylaxis, single-dose antibiotic ther-
apy or starting 3–5 days before the surgical procedure.The main outcome was postoperative infection. The
main objective was to determine if there were differences
in the results depending on the different timing of
administration of antibiotic prophylaxis.
The search was conducted in PubMed, the Literatura
Latino-Americana e do Caribe em Ciências da Saúde
database (LILACS), EBSCO, and Cochrane databases
using the Medical Subject Heading (MeSH) terms ‘an-
tibiotic prophylaxis’ AND ‘urologic surgical procedures’
AND ‘asymptomatic bacteriuria’. The search was lim-
ited to humans and there were no restrictions on lan-
guage or sample size. Studies published up to August
2015 were included with no date restriction.
Inclusion criteria
Randomised clinical trials and observational studies
(cohort studies, case-control studies) that compared
the start and treatment regimens of antibiotic prophy-
laxis in patients with AB scheduled for a urological sur-
gical procedure were included. An additional inclusion
criterion was that patients had to be followed for a min-
imum of 7 days.
Titles and abstracts of the retrieved studies were
reviewed to determine if they met the inclusion criteria.
The full text was consulted to determine definitive inclu-
sion or not if there were doubts.
The most frequent reasons for rejecting investigations
were: (i) patients had had a previous transplantation; (ii)
patients with active UTIs; (iii) the primary outcome was
not infection of the surgical site; (iv) the follow-up was
<7 days after surgery, and (v) information was
incomplete.
The main outcome variable was post-surgical infec-
tious complications and secondary outcomes were read-
missions and hospital stay. To consider a surgical site
infection we used the definition of the Center for Disease
Control of the USA: infection has to occur within
30 days after the surgical procedure, and it affects the
skin, subcutaneous tissue, muscle or the manipulated
organ during surgery.
Study quality assessment
Two experts independently assessed the quality of all
papers included. The methodological quality and the
236 Ramos et al.external validity of the included studies were evaluated
using a specifically developed scale where five items were
evaluated with a score range between 0 and 10 points.
The items considered were: type of study, sample size,
follow-up period, comparable groups at baseline, and
control covariates. Each item was rated between 0 and
2 points, and a study was considered as being of good
quality if it had P7 points. Studies rated at 5–6 points
were considered as being of moderate quality and those
of 64 points as low quality. The scale used with its items
is shown in Table 1.
Additionally, the quality of the studies was assessed
using the method recommended by the Cochrane Col-
laboration for measurement biases (domain-based
assessment) [9]. The possibility of presenting selection
bias (randomisation), detection and control of bias
(masking), bias for losses, and reporting biases was
scored as low, medium or high.
Results
The literature search retrieved 14 investigations, with
nine fulfilling the inclusion criteria. Five studies analysed
antibiotic prophylaxis for transrectal prostate biopsy
[10–14], only one study evaluated antibiotic prophylaxis
for urological procedures at a general level [15], and the
remaining studies analysed antibiotic therapy for cys-
toscopy, transurethral prostatic resection and urethral
lithotripsy [16]. The studies were published between
1998 and 2013, and were carried out in Chile, Colombia,
Taiwan, India, France, Turkey, and China.Most of them
were written in English (77.8%). The characteristics of
the included studies are shown in Table 2.Table 1 Quality scale used to score the included studies.
Item assessed Characteristic Weight












Comparable groups Heterogeneous 0
Homogeneous 2




* Age and sex.Of the nine studies included, eight evaluated antibi-
otic prophylaxis regardless of the time of treatment ini-
tiation or the presence of AB (Table 2); only one of them
assessed the duration of antibiotic prophylaxis in
patients with AB (Table 2).
Four studies showed a significant reduction in the
rate of surgical infection in the intervention group; of
these, two were conducted in patients scheduled for
transrectal prostate biopsy and their comparison group
received placebo [10,14]. They also had two intervention
groups each having the same antibiotics but with differ-
ent durations of treatment, without significant differ-
ences between the intervention groups.
The first study conducted in China, between 1998 and
2001, included 192 patients. It concluded that an oral
single dose of prophylactic antibiotics (ciprofloxacin
500 mg and metronidazole 400 mg) is effective and safe
to prevent infectious complications in patients undergo-
ing transrectal prostate biopsy [14]; the second, per-
formed in India between 1996 and 1998 also concluded
that an oral single dose (ciprofloxacin 500 mg and
tinidazole 600 mg) was adequate as prophylaxis for
transrectal prostate biopsy [10]. Both studies used pla-
cebo for comparison and its intervention groups were
different in antibiotic and duration (Table 2).
Another study conducted in Chile, between 2001 and
2002, in patients scheduled for transurethral resection
found a lower infection rate in the intervention group
(cefazolin 1 g i.v. every 8 h in 1 day and ciprofloxacin
every 12 h until removal of the bladder catheter) com-
pared with the comparison group (cefazolin 1 g i.v.
every 8 h by two doses followed by nitrofurantoin
100 mg orally until removal of the urinary catheter);
however, the presence of AB before the procedure was
not determined [17]. The fourth study conducted in Italy
included 138 patients and showed a lower rate of infec-
tion in the intervention group (piperacillin tazobactam
2250 mg i.m. every 12 h for 2 days) compared with the
comparison group (ciprofloxacin 500 mg orally ever
12 h for 7 days); however, again the presence of AB
before the procedure was not determined [11].
The remaining four studies found no significant dif-
ferences in reducing infectious complications. One was
conducted in Colombia in 138 patients with negative
urine cultures with an indication for cystoscopy, where
they compared single-dose levofloxacin 500 mg as a pro-
phylactic antibiotic with placebo and found no differ-
ence in infectious complications [18]. Another study in
France with 288 men scheduled for transrectal prostate
biopsy, found no difference between the duration of
antibiotic therapy (single dose vs 3 days) with ciproflox-
acin 500 mg orally, without checking for the presence of
AB [12]. The third study, conducted in Taiwan between
2009 and 2012 in 206 patients with negative urine cul-
tures scheduled for ureterorenoscopic lithotripsy found
no differences in infectious complications in the three









Colombia Group I: 138
Group C:
138
Levofloxacin 500 mg single
dose
Placebo 500 mg single dose The incidence of UTI







Chile Group I: 45
Group C: 45
Cefazolin 1 g i.v.
preoperatively and every 8 h
during the first day (3 doses).
Followed by ciprofloxacin
250 mg orally every 12 h until
removal of the bladder
catheter
Cefazolin 1 g i.v.
preoperatively and 8 h later (2
doses). Nitrofurantoin
followed by 1000 mg orally
daily until removal of the
bladder catheter
Post-surgical UTI
occurred in 2% of






Italy Group I: 72
Group C: 66
Piperacilin tazobactam
2250 mg i.m. every 12 h for
2 days
Ciprofloxacin 500 mg orally
every 12 h for 7 days
Post-surgical UTI
occurred in 0% in






France Group I: 139
Group C:
149
Ciprofloxacina 500 mg orally
2 h before the procedure










1. Cefazolin 1 g 60 min before
the procedure
2. Ceftriazone 1 g 60 min
before the procedure
3. Levofloxacin 500 mg 2 h
before the procedure
No antibiotics The rate of infection
after the procedure was
1.3% in Group I and





Benin Group I: 42
Group C: 45
Ciprofloxacin 500 mg orally
and metronidazole 400 mg
every 8 h for 1 day
Ciprofloxacin 500 mg orally
and metronidazole 400 mg
every 8 h for 5 days
The rate of infection
after the procedure was
19% in Group I and




China Group I1: 64
Group I2: 66
Group C: 62
1. Ciprofloxacin 500 mg and
metronidazole 400 mg
2. Ciprofloxacin 500 mg and
metronidazole 400 mg for
3 days
Placebo (no antibiotics) The incidence of
infectious complications
in the Group C was











India Group I1: 79
Group I2: 77
Group C: 75
1. Single dose of ciprofloxacin
500 mg and 600 mg
tinidazole
2. Single dose of ciprofloxacin
500 mg and tinidazole
600 mg every 12 h for
3 days
Placebo tablet twice a day for
3 days (no antibiotics)
The incidence of
infectious complications
in Group C was higher
(19%) than in the Group





Turkey Group I: 31
Group C: 28
Single dose of an appropriate
antibiotic, determined by
antimicrobial sensitivity
testing, 30–60 min before
surgery
Antibiotic treatment before
surgery until negative culture
None of the patients
presented infectious
complications
Differences in length of




Group I, intervention group; Group C, comparison group.
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that received no antibiotic [19]. Finally, a study con-
ducted in Benin in 87 patients undergoing transrectal
prostate biopsy found no significant differencescomparing both groups, with no monitoring for the
presence of AB [13].
Only the study by Sayin Kutlu et al. [15] conducted in
Turkey between 2005 and 2008 in 59 patients scheduled
238 Ramos et al.for a urological procedure assessed the duration of
antibiotic prophylaxis in patients with AB, indicating
that there were no significant differences between
single-dose therapy (30–60 min before the procedure)
with an antibiotic treatment lasting 3–15 days until the
urine was sterile before surgery. That study also found
significant differences in the reduction of hospital stay
and costs of antimicrobials in the single-dose group
(P < 0.001).
Quality of the included studies
The quality of the included studies was not high. Only
two had >7 points in the ad hoc scale and four had a
score of 5–6 points. The average score was 5.3 points.
Discussion
This is the first systematic review to analyse the type of
antibiotic prophylaxis and its adequate duration for
patients with AB scheduled for invasive urological pro-
cedures. The use of antibiotic prophylaxis for urological
surgical procedures has sufficient clinical evidence for
reducing post-surgical urinary infections and it is recom-
mended in the 2015 Canadian Urological Association
antibiotic prophylaxis guideline for urological proce-
dures [8].
From the studies reviewed, no one was carried out in
patients with AB, as the variable was not controlled for
or because they were carried out in patients with nega-
tive urine cultures. The purpose of the studies evaluated
was to identify the effectiveness of antibiotic prophylaxis
for urological procedures, without evaluating the ade-
quate scheduling of this therapy. A further limitation
of the studies was the small sample size, which made it
difficult to have statistically significant results due to
the low infection rate both in the intervention and in
the control/placebo groups.
Schemes of antibiotic prophylaxis
The included studies had multiple schemes of antibiotic
prophylaxis, with variations in the antibiotics used,
dosage, and duration of treatment. For example, the
most used antibiotic was ciprofloxacin in the studies of
Aaron et al. [10], Yang et al. [14], Agbugui et al. [13],
Briffaux et al. [12], Valdevenito and Cormio [17], as sin-
gle or combined therapy. The study schemes were all dif-
ferent and the most utilised duration of therapy was
1 day or single-doses, without significant differences in
the intervention groups. The difference observed in the
included studies was a decrease in the risk of post-
surgical infections in patients undergoing antibiotic pro-
phylaxis compared with those of the placebo group. The
above reflects the guideline recommendations, where
antibiotic prophylaxis for AB is recommended, althoughthere is no specific recommendation on the duration of
therapy [1,5,8].
All studies employed wide-spectrum antibiotics, with
ciprofloxacin and levofloxacin the most common, so
may generate multi-resistant bacteria by selective pres-
sure [20]. Regarding the follow-up to assess post-
surgical infectious complications, the maximum length
was 5 weeks in the Chilean study [17] with an average
of 10 days after the urological intervention.
It is noteworthy that in two studies by Garcia-
Perdomo et al. [18] and Hsieh et al. [19], the intervention
group was compared with the placebo group and they
did not find significant differences, which suggests that
antibiotic prophylaxis does not reduce the risk of infec-
tious complications. However, these studies had a low
statistical power due to their small sample size, which
makes it difficult to identify significant differences.
Methodological aspects
The sample size of the included studies was very hetero-
geneous, from 59 patients to >200. This sample size is
insufficient to show an effect of antibiotic treatment
and therefore cannot either ascertain if it is more or less
effective for specific subgroups (i.e. age, gender or differ-
ent urological procedures).
One of the most key problems of the studies included
is that most of the studies (89%) did not control for the
variable of AB before the intervention, whilst in others it
was done in patients with negative urine cultures. Only
the study of Sayin Kutlu et al. [15] controlled for AB,
but this study had a low sample size (31 patients in the
intervention group and 28 in the comparison group)
and did not control for confounding variables such as
permanent vesicle catheter or immunosuppression. In
addition, most of the urological procedures were inser-
tion or change of JJ catheters.
Limitations and advantages
The main limitation of the present review is that it does
not provide evidence about the research question (ther-
apy and starting time of antibiotic prophylaxis to pre-
vent infection in urological procedures in patients with
AB). Another limitation is the impossibility of applying
meta-analytic techniques due to the high heterogeneity
of the included studies (different sample sizes, different
groups of comparison, including placebo, different sur-
gical indications, etc.) that does not make them compa-
rable. Another important limitation is that most of the
studies did not control for variables such as AB, surgical
procedures, and prophylaxis duration. A last limitation
is that only two studies had a quality score of >7 points
in the ad hoc quality scale.
The main advantage of the study is the use of a sys-
tematic review, as this methodology analyses the avail-
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In this same way, the quality scale developed for this
review helps to grade the quality of studies included
using a homogeneous approach.
The guide diagnosis and treatment of AB in adults
recommended clinical trials to determine the duration
of therapy for the treatment of AB in patients scheduled
for urological surgery.
To conclude, it is important to establish the duration
and type of treatment for antimicrobial therapy for sur-
gical prophylaxis in patients with AB that are going to
receive urological invasive procedures. If we can show
that a short duration of antibiotic therapy is equally
effective and safe this would decrease hospital stay, the
delay in time of surgery, the costs in providing services,
and most importantly, the risk would be controlled
infection selection of multi-resistant bacteria, which
could lead to generating a health policy impact in this
group of patients.
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